Ventripoint Diagnostics has partnered with the Ollie Hinkle Heart Foundation to increase access to AI-powered cardiac imaging for children and adults with congenital and childhood-onset heart disease. The collaboration will place advanced VMS+™ cardiac imaging systems in healthcare networks supported by the foundation, improving diagnostic accuracy and clinical decision-making. This partnership aims to reduce barriers to advanced heart imaging, inspired by families' experiences, and enhance care for patients through innovative technology and community engagement. The initiative reflects a commitment to better outcomes by combining cutting-edge AI tools with patient-centered support models.
Virtual Investor Conferences announced that presentations from the June 24-25 Life Sciences Virtual Investor Forum are now accessible on-demand for 90 days. This event featured multiple life sciences companies presenting to investors, with opportunit...
Vaxart, a clinical-stage biotech company, has published a presentation urging shareholders to vote for all six of its director nominees at the upcoming Annual Meeting. The company highlights its progress in developing oral vaccines for COVID-19, noro...
Axsome Therapeutics has initiated the FOCUS-3 Phase 3 clinical trial to evaluate solriamfetol as a treatment for adolescents aged 12 to under 18 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to asse...
WuXi AppTec highlights how the increasing structural complexity of small molecules, such as targeted protein degraders and covalent inhibitors, is transforming drug research and development. These new molecules require advanced, integrated approaches...
At its Annual General Meeting on June 25, 2026, Fury Gold Mines shareholders approved fixing the board size at six directors and elected all nominated directors. PricewaterhouseCoopers LLP was appointed as the company's auditor. Shareholders also ren...
